retatrutide ly3437943 triple agonist glp-1 gip glucagon Biggest obesity news 🚨 TRIUMPH-1 results are here: Retatrutide's phase 3 trial showed up to 28% average weight loss over 80 weeks — with nearly half of patients losing over 30% of retatrutide triple agonist glp-1 gip
Pay in 4 interest-free payments of $5.91 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22





























